# Countdown to Alzheimer’s: Blood Test Breakthrough!

Newsy: Alzheimer’s News Weekly
Published: 2026-02-23T13:30:00.270Z
Source: https://newsyai.com/edition/e5823a8a-671f-4690-84f2-25f88606428a
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# Alzheimer’s Treatment Briefing
Coverage period: February 17–23, 2026 (United States)

Below are this week’s most meaningful, truly new developments, ranked by impact on treatment and access.

1) A simple blood test now predicts “when,” not just “if,” symptoms may start
- Overview
  - A Nature Medicine study shows that one blood marker (p‑tau217) can estimate how many years remain until memory and thinking problems begin—typically within a 3–4 year window. The “symptom clock” runs faster in older adults (about 11 years from a positive test at age 80 versus ~20 years at age 60). Not ready for clinic use yet, but the model is public so others can refine it. [Nature Medicine](https://www.nature.com/articles/s41591-026-04206-y) | News coverage: [Washington Post](https://www.washingtonpost.com/health/2026/02/19/alzheimers-tests-symptom-onset-predictions/) and [The Times](https://www.thetimes.com/uk/healthcare/article/alzheimers-researchers-find-clock-for-onset-of-symptoms-2gfqp08fx). ([nature.com](https://www.nature.com/articles/s41591-026-04206-y?utm_source=openai))
- Why this matters
  - Trials can enroll people who are most likely to develop symptoms during the study window—speeding answers.
  - If early treatment works best, a reliable “when” clock could eventually guide earlier starts and better planning.

2) J&J pauses enrollment in a preventive anti‑tau vaccine study
- Overview
  - Johnson & Johnson temporarily paused new enrollment in RETAIN, a Phase 2b trial of ACI‑35.030/JNJ‑2056 (an anti‑tau immunotherapy) for people before symptoms. The company cites recruitment and trial‑design review; the study itself continues and there’s no new safety concern. [Fierce Biotech](https://www.fiercebiotech.com/biotech/jj-halts-enrollment-phase-2-trial-ac-immune-partnered-alzheimers-therapy). ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/jj-halts-enrollment-phase-2-trial-ac-immune-partnered-alzheimers-therapy?utm_source=openai))
- Why this matters
  - Tau‑targeting treatments are the key “next step” after amyloid‑clearing drugs. A recruitment pause highlights how hard true prevention trials are—and why better risk clocks (like p‑tau217 above) could unlock them.

3) Oral drug ALZ‑801 reports positive signals in APOE4/4 patients at the MCI stage
- Overview
  - Pharmacy Times summarized new company‑reported data: in APOE4/4 patients with very early symptoms (MCI), ALZ‑801 (valiltramiprosate) showed benefits on thinking, daily function, and brain volume, with supportive blood markers and without the brain‑swelling risk seen with some antibodies. Note: this is based on company releases; peer‑reviewed, full Phase 3 outcomes are still pending. [Pharmacy Times](https://www.pharmacytimes.com/view/investigational-therapy-alz-801-shows-clinical-efficacy-in-mci-stage-of-alzheimer-disease) | Company background updates: [Alzheon press page](https://alzheon.com/press-releases/). ([pharmacytimes.com](https://www.pharmacytimes.com/view/investigational-therapy-alz-801-shows-clinical-efficacy-in-mci-stage-of-alzheimer-disease?utm_source=openai))
- Why this matters
  - If confirmed, a safe, oral, antibody‑free option for a genetically high‑risk group would broaden choices and simplify care. For now, treat this as promising but provisional.

4) Air‑pollution study strengthens the case for prevention policies
- Overview
  - An Emory‑led analysis of 27.8 million older Americans links long‑term exposure to fine particle pollution (PM2.5) with a higher risk of Alzheimer’s, including effects not explained by stroke, high blood pressure, or depression. Published in PLOS Medicine, widely covered in the press. [Financial Times](https://www.ft.com/content/35c5904e-c1bc-452c-9f38-29b6b1b77066) summary. ([ft.com](https://www.ft.com/content/35c5904e-c1bc-452c-9f38-29b6b1b77066?utm_source=openai))
- Why this matters
  - Cleaner air is a brain‑health policy. For clinics, it supports counseling on air‑quality steps (home filtration, avoiding outdoor exercise on bad‑air days), alongside medical treatments.

5) Oral cortisol‑blocking candidate Xanamem clears interim check, trial continues
- Overview
  - Independent monitors reviewed mid‑study data from Actinogen’s Phase IIb/III XanaMIA trial (mild–moderate Alzheimer’s) and recommended continuing as planned; final results expected November 2026. [Edison Group analysis](https://www.edisongroup.com/research/xanamia-passes-interim-analysis-and-marches-on/BM-2835/). ([edisongroup.com](https://www.edisongroup.com/research/xanamia-passes-interim-analysis-and-marches-on/BM-2835/?utm_source=openai))
- Why this matters
  - A once‑daily pill with a non‑amyloid mechanism would diversify options. The green light to continue is not proof of benefit—but it keeps this alternative path alive.

What this means for care right now
- Use blood tests to triage earlier—and keep watch
  - This week’s p‑tau217 “symptom clock” isn’t for routine care yet, but it reinforces using validated blood biomarkers to route patients faster to the right next step (confirmatory scans or treatment evaluation). ([nature.com](https://www.nature.com/articles/s41591-026-04206-y?utm_source=openai))
- Set expectations on the pipeline
  - Anti‑tau strategies face real‑world hurdles (e.g., recruitment). Share that timelines can shift, but prevention‑focused trials are advancing. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/jj-halts-enrollment-phase-2-trial-ac-immune-partnered-alzheimers-therapy?utm_source=openai))
- Offer practical prevention advice alongside medicines
  - Discuss air‑quality precautions, exercise, sleep, blood‑pressure control, and hearing support—evidence‑based steps that complement disease‑slowing drugs. ([ft.com](https://www.ft.com/content/35c5904e-c1bc-452c-9f38-29b6b1b77066?utm_source=openai))
- Track emerging oral options
  - ALZ‑801 and Xanamem are not approved; consider them “watch list” candidates that could pair with, or offer alternatives to, antibody therapies if results hold up. ([pharmacytimes.com](https://www.pharmacytimes.com/view/investigational-therapy-alz-801-shows-clinical-efficacy-in-mci-stage-of-alzheimer-disease?utm_source=openai))

Sources
- Predicting onset of symptomatic Alzheimer’s disease with plasma p‑tau217 clocks (Feb 19, 2026), Nature Medicine. ([nature.com](https://www.nature.com/articles/s41591-026-04206-y?utm_source=openai))
- News coverage of the symptom clock: Washington Post; The Times (Feb 19–20, 2026). ([washingtonpost.com](https://www.washingtonpost.com/health/2026/02/19/alzheimers-tests-symptom-onset-predictions/?utm_source=openai))
- J&J pauses enrollment in AC Immune–partnered anti‑tau trial (Feb 19, 2026), Fierce Biotech. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/jj-halts-enrollment-phase-2-trial-ac-immune-partnered-alzheimers-therapy?utm_source=openai))
- ALZ‑801 update in MCI (Feb 16–17, 2026), Pharmacy Times; Alzheon press updates (Feb 3, 2026). ([pharmacytimes.com](https://www.pharmacytimes.com/view/investigational-therapy-alz-801-shows-clinical-efficacy-in-mci-stage-of-alzheimer-disease?utm_source=openai))
- Air pollution and Alzheimer’s risk (Feb 18–19, 2026) coverage, Financial Times (study in PLOS Medicine). ([ft.com](https://www.ft.com/content/35c5904e-c1bc-452c-9f38-29b6b1b77066?utm_source=openai))
- Xanamem XanaMIA trial continues after interim review (Feb 20, 2026), Edison Group. ([edisongroup.com](https://www.edisongroup.com/research/xanamia-passes-interim-analysis-and-marches-on/BM-2835/?utm_source=openai))

If a week brings few truly new, treatment‑relevant developments, I will keep sections brief rather than repeat prior items.
